One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Taysha Gene Therapies, Inc.
TSHA · NMS · Healthcare · Biotechnology
Current price
$4.28
52-week range
$3.46 - $7.30
Market cap
$1.39B
Balance sheet
Healthy
-1,753.94x Concerning
Net cash $398.69M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Taysha Gene Therapies, Inc.
Taysha Gene Therapies develops special medicines that aim to fix genetic diseases affecting the brain and nerves, with the goal of helping people with rare conditions. Their funding primarily comes from investors and partnerships, which is crucial because developing these complex treatments requires significant financial resources.
How the company got here
Taysha Gene Therapies was founded in 2020 with the goal of developing gene therapies for severe genetic diseases affecting the central nervous system (CNS). It was established around technology licensed from The University of Texas Southwestern Medical Center. The company went public in 2020 and initially focused on a broad range of CNS gene therapy programs. However, it later refined its strategy to concentrate on its most promising candidates, particularly for rare neurological conditions. A significant development was a strategic transaction with Astellas Pharma in 2023, which has helped to advance its clinical programs.
What it actually does
Taysha Gene Therapies is a biotechnology company that develops gene therapies. Gene therapy is a medical approach that aims to treat diseases by correcting the underlying genetic problem. Taysha focuses on developing treatments for severe genetic disorders that affect the brain and nervous system, using a technology called adeno-associated virus (AAV)-based gene therapy. This involves using a modified virus as a delivery vehicle to introduce a healthy gene into a patient's cells to replace or correct a faulty gene causing the disease. The company is in the clinical-stage, meaning its therapies are currently being tested in human trials and are not yet approved for sale.
Gene Therapy Segment
Taysha Gene Therapies operates primarily within a single business segment: Gene Therapy. This segment is dedicated to the research, development, and eventual commercialization of adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS). Monogenic diseases are those caused by a defect in a single gene. The company's efforts in this segment are focused on creating treatments that address the root cause of these debilitating neurological conditions. While Taysha has generated some revenue, it is primarily from collaborations and partnerships rather than product sales, as its therapies are still in development. The company's revenue in the past year was approximately $9.77 million, all of which came from its Gene Therapy segment, with the United States being its primary market.
What management is betting on now
Taysha's main strategic focus is on advancing its lead gene therapy candidate, TSHA-102, for the treatment of Rett syndrome. This rare neurodevelopmental disorder currently has no approved treatments that address its genetic cause. Taysha is concentrating its resources on this program, aiming to generate strong clinical data to support regulatory approval. The company is also exploring innovative technologies, such as its miRARE platform, to precisely control gene expression and enhance the safety of its therapies. This focused approach is designed to de-risk development and increase the probability of success for its most promising candidate.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-21.65M
FY2024 Q4
$-18.31M
FY2025 Q1
$-22.40M
FY2025 Q2
$-20.18M
FY2025 Q3
$-24.27M
FY2025 Q4
$-26.97M
FY2026 Q1
$-40.90M
FY2026 Q2
$-40.43M
Revenue
$0.00
Net income
$-46.64M
Diluted EPS
-0.13
Operating cash flow
$-40.42M
Free cash flow
$-40.43M
Fetching…
Sources
Revenue
$0.00
Net income
$-42.41M
Diluted EPS
-0.12
Operating cash flow
$-40.88M
Free cash flow
$-40.90M
Fetching…
Sources
Revenue
$5.49M
Net income
$-27.85M
Diluted EPS
-0.08
Operating cash flow
$-26.72M
Free cash flow
$-26.97M
Fetching…
Sources
Revenue
$0.00
Net income
$-32.73M
Diluted EPS
-0.09
Operating cash flow
$-24.17M
Free cash flow
$-24.27M
Fetching…
Sources
Revenue
$1.99M
Net income
$-26.88M
Diluted EPS
-0.09
Operating cash flow
$-20.18M
Free cash flow
$-20.18M
Fetching…
Sources
Revenue
$2.30M
Net income
$-21.53M
Diluted EPS
-0.08
Operating cash flow
$-22.02M
Free cash flow
$-22.40M
Fetching…
Sources
Revenue
$2.02M
Net income
$-18.79M
Diluted EPS
-0.07
Operating cash flow
$-18.31M
Free cash flow
$-18.31M
Fetching…
Sources
Revenue
$1.79M
Net income
$-25.52M
Diluted EPS
-0.10
Operating cash flow
$-21.61M
Free cash flow
$-21.65M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $4.28
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $398.7M - more cash than debt. Interest coverage -1753.9x.
Net debt
$-398.69M
Interest coverage
-1,753.94x
Taysha Gene Therapies, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
TSHA
BASELINE
Taysha Gene Therapies, Inc.
Total debt $56.71M Interest coverage -1,753.94x This is the baseline the peer rows are being compared against.
Total debt $230.14M Interest coverage -15.10x Neither company has much profit cushion over interest right now.
Total debt $2.94B Interest coverage 5.63x This peer still has a real interest-payment cushion, while TSHA does not.
Total debt $203.83M Interest coverage -55.80x Neither company has much profit cushion over interest right now.
Total debt $44.71M Interest coverage -7.91x Neither company has much profit cushion over interest right now.
What you should know
The case for and against TSHA
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -47.1% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-9.25x
P/B
3.60x
P/S
254.25x
EV/EBITDA
-6.54x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
100.0%
Operating margin
-2,792.3%
Net margin
0.0%
ROE
-47.1%
ROA
-23.8%
Health
Liquidity and balance-sheet strength
Debt / equity
0.15x
Current ratio
17.77x
Quick ratio
17.53x
Total debt
$56.71M
Total cash
$455.41M
Growth
How the business has been compounding
Revenue TTM
$5.49M
Revenue 5Y CAGR
57.5%
EPS TTM
-0.41
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-132.19M
Free CF TTM
$-93.83M
FCF margin
-1,710.6%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—